TJP1 and Parkinson disease: In a mouse model of Parkinson’s disease (PD), 6-shogaol counteracted the decreases of occludin and ZO-1 proteins and reduced the production of tumor necrosis factor-alpha (TNF-α) and IL-1β in the colon, thereby preventing inflammation-induced gastrointestinal dysfunction [14].